الفهرس Only 14 pages are availabe for public view
 |  | from | 181 |  |  |
| | | from | 181 | | |
Abstract
Patients : Female patients between the ages of 18-80 yrs. Baseline Hematological, Renal and Liver laboratory profiles were within accepted ranges. Patients were surgically fit to undergo radical surgery. Patients had to be ECOG Performance status 0-2 to start chemotherapy Patients will pathologically proven Ovarian Cancer and records showed follow-up for at least 6 months. Women who stopped their treatment for non-medical reasons (social or psychological or financial). Were excluded .Any records of other malignancy at other sites were excluded from this analysis. Methodology: Records were evaluated to answer if the patient underwent Radical surgery, received adjuvant systemic treatment, the type of chemotherapy, duration of the adjuvant treatment and the period between last cycle od adjuvant and any disease relapse. For metastatic patients; what type of chemotherapy used as first line and its response, second line and its response and if third was given. Also the study assess the common drug related toxicities and the qualit y of life for the patients. Results: DFS period is calculated as the interval through the first Progression after receiving primary treatment. Progression was detected clinically and/or radiologically, after receiving adjuvant Chemotherapy. OS period is measured as the interval between the date of histo-pathological confirmation of disease (either Radical surgery or biopsies) and death or date of the last follow-up evaluation. Conclusion: We found that in EOC subtype the patients are almost a decade younger than western patients. The results of DFS and OS were comparable to the international statistics. There is no clear guidelines for second line protocols. Limited financial resources did not affect the management of patients concerning radical surgery and adjuvant therapy